|
|
|
|
Tuesday, October 1, 2019
Trovagene (TROV)
Number of Patients with a Complete Response Increases in AML Study
Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- AML study update at ESMO. Trovagene presented updated data from the Phase 1b/2 study assessing Onvansertib in combination with standard-of-care chemotherapy (low-dose cytarabine (LDAC) or decitabine) in acute myeloid leukemia (AML). Four patients among 24 achieved objective responses, two with complete remission (CR) and two with incomplete hematologic recovery (iCR).
- Higher doses of Onvansertib are more effective. The patients who were treated with the highest two doses (27, 40 mg/m2) of Onvansertib demonstrated…
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.